Sanofi News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

20.05.24	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (EN, Sanofi-Aventis)
20.05.24	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM (GlobeNewswire)
13.05.24	Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod (RTTNews)
13.05.24	Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis (RTTNews)
13.05.24	Sanofi To Invest Over EUR 1 Bln Further For Biomanufacturing In France (RTTNews)
13.05.24	Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty (EN, Sanofi-Aventis)
13.05.24	Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty (GlobeNewswire)
10.05.24	Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine (RTTNews)
10.05.24	Sanofi Strikes COVID-19 Vaccine Agreement With Novavax; To Take Minority Stake (RTTNews)
10.05.24	Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines (GlobeNewswire)
10.05.24	Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines (EN, Sanofi-Aventis)
02.05.24	Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations (EN, Sanofi-Aventis)
02.05.24	Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations (GlobeNewswire)
30.04.24	Press Release: Annual General Meeting of April 30, 2024 (EN, Sanofi-Aventis)
30.04.24	Press Release: Annual General Meeting of April 30, 2024 (GlobeNewswire)
26.04.24	Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases (EN, Sanofi-Aventis)
25.04.24	Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up (RTTNews)
25.04.24	Sanofi Q1 Profit Drops, Sales Rise; Confirms FY24 Outlook (RTTNews)
25.04.24	Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance (EN, Sanofi-Aventis)
25.04.24	Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance (GlobeNewswire)
23.04.24	Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia (RTTNews)
23.04.24	Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia (GlobeNewswire)
23.04.24	Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia (EN, Sanofi-Aventis)
17.04.24	Why IGM Biosciences Is Rising In Pre-market? (RTTNews)
17.04.24	Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (EN, Sanofi-Aventis)
17.04.24	Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (GlobeNewswire)
12.04.24	Sanofi: Information concerning the total number of voting rights and shares - March 2024 (GlobeNewswire)
08.04.24	Sanofi - AGM 30.04.2024 - Availability of Preparatory documents (GlobeNewswire)
22.03.24	Press Release: Availability of the Q1 2024 Memorandum for modelling purposes (GlobeNewswire)
22.03.24	Press Release: Availability of the Q1 2024 Memorandum for modelling purposes (EN, Sanofi-Aventis)
15.03.24	Sanofi: Information concerning the total number of voting rights and shares - February 2024 (GlobeNewswire)
11.03.24	Sanofi's Phase 2b Results Support Amlitelimab's Potential In Atopic Dermatitis (RTTNews)
11.03.24	Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis (EN, Sanofi-Aventis)
11.03.24	Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis (GlobeNewswire)
24.02.24	Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria (GlobeNewswire)
24.02.24	Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria (EN, Sanofi-Aventis)
24.02.24	Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma (EN, Sanofi-Aventis)
23.02.24	Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report (GlobeNewswire)
23.02.24	Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report (EN, Sanofi-Aventis)
23.02.24	Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation (RTTNews)
23.02.24	Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation (EN, Sanofi-Aventis)
23.02.24	Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation (GlobeNewswire)
22.02.24	Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors (GlobeNewswire)
22.02.24	Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors (EN, Sanofi-Aventis)
20.02.24	Sanofi: Information concerning the total number of voting rights and shares - January 2024 (GlobeNewswire)
20.02.24	Private Equity Firms Show Interest In Sanofi's Consumer Health Unit: Bloomberg (RTTNews)
16.02.24	Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment (RTTNews)
16.02.24	Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) (GlobeNewswire)
16.02.24	Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) (EN, Sanofi-Aventis)
15.02.24	Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:17		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus